GCA
HAE icon

Gideon Capital Advisors’s Haemonetics HAE Stock Holding History

Gideon Capital Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,040
Closed -$528K – 336
2019
Q1 		$528K Buy
+6,040
New +$549K 0.19% 157
2018
Q3 		– Sell
-2,927
Closed -$262K – 405
2018
Q2 		$262K Buy
+2,927
New +$247K 0.13% 288

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Gideon Capital Advisors's HAE Position: Q2 2019 in Review

Gideon Capital Advisors sold out of Haemonetics (HAE) in Q2 2019, closing a stake of 6,040 shares — an estimated $528K sold.

Gideon Capital Advisors first reported a position in HAE in Q2 2018 and held it in 2 quarters. The position peaked at $528K in Q1 2019. 256 funds tracked by Wall St. Rank hold HAE as of Q2 2019.

  • Gideon Capital Advisors reported no remaining Haemonetics position as of Q2 2019 after selling out during the quarter.
  • Gideon Capital Advisors sold 6,040 Haemonetics shares in Q2 2019, an estimated $528K.
  • Gideon Capital Advisors first reported a position in Haemonetics in Q2 2018 and held it in 2 quarters.
  • Gideon Capital Advisors's Haemonetics position peaked at $528K in Q1 2019.
  • 256 funds tracked by Wall St. Rank held Haemonetics as of Q2 2019.

Based on Gideon Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.